|
1.
|
Lim E, Metzger-Filho O and Winer EP: The
natural history of hormone receptor-positive breast cancer.
Oncology (Williston Park). 26:688–694. 6962012.PubMed/NCBI
|
|
2.
|
Murphy LC, Seekallu SV and Watson PH:
Clinical significance of estrogen receptor phosphorylation. Endocr
Relat Cancer. 18:R1–R14. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Becker MA, Ibrahim YH, Cui X, Lee AV and
Yee D: The IGF pathway regulates ERα through a S6K1-dependent
mechanism in breast cancer cells. Mol Endocrinol. 25:516–528.
2011.
|
|
4.
|
de Leeuw R, Neefjes J and Michalides R: A
role for estrogen receptor phosphorylation in the resistance to
tamoxifen. Int J Breast Cancer. 2011:2324352011.PubMed/NCBI
|
|
5.
|
Green KA and Carroll JS:
Oestrogen-receptor-mediated transcription and the influence of
co-factors and chromatin state. Nat Rev Cancer. 7:713–722. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
McCarty KS Jr, Miller LS, Cox EB, Konrath
J and McCarty KS Sr: Estrogen receptor analyses. Correlation of
biochemical and immunohistochemical methods using monoclonal
antireceptor antibodies. Arch Pathol Lab Med. 109:716–721.
1985.
|
|
7.
|
Riggins RB, Schrecengost RS, Guerrero MS
and Bouton AH: Pathways to tamoxifen resistance. Cancer Lett.
256:1–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Thibault C, Khodari W, Lequoy M, Gligorov
J and Belkacémi Y: HER2 status for prognosis and prediction of
treatment efficacy in adenocarcinomas: A review. Crit Rev Oncol
Hematol. 13:Apr 5–2013.(Epub ahead of print).
|
|
9.
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Cittelly DM, Das PM, Salvo VA, Fonseca JP,
Burow ME and Jones FE: Oncogenic HER2Δ16 suppresses miR-15a/16 and
deregulates BCL-2 to promote endocrine resistance of breast tumors.
Carcinogenesis. 31:2049–2057. 2010.
|
|
11.
|
Yamashita H, Nishio M, Toyama T, et al:
Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118
and high phosphorylation of ERalpha serine 167 improve survival in
ER-positive breast cancer. Endocr Relat Cancer. 15:755–763. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Métivier R, Gay FA, Hübner MR, et al:
Formation of an hER alpha-COUP-TFI complex enhances hER alpha AF-1
through Ser118 phosphorylation by MAPK. EMBO J. 21:3443–3453.
2002.PubMed/NCBI
|
|
13.
|
Zhu C, Qi X, Chen Y, Sun B, Dai Y and Gu
Y: PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in
IGF-1-induced VEGF-C upregulation in breast cancer. J Cancer Res
Clin Oncol. 137:1587–1594. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Tai W, Qin B and Cheng K: Inhibition of
breast cancer cell growth and invasiveness by dual silencing of
HER-2 and VEGF. Mol Pharm. 7:543–556. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Mintz PJ, Habib NA, Jones LJ, et al: The
phosphorylated membrane estrogen receptor and cytoplasmic signaling
and apoptosis proteins in human breast cancer. Cancer.
113:1489–1495. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Guo JP, Shu SK, Esposito NN, Coppola D,
Koomen JM and Cheng JQ: IKKepsilon phosphorylation of estrogen
receptor alpha Ser-167 and contribution to tamoxifen resistance in
breast cancer. J Biol Chem. 285:3676–3684. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Motomura K, Ishitobi M, Komoike Y, et al:
Expression of estrogen receptor beta and phosphorylation of
estrogen receptor alpha serine 167 correlate with progression-free
survival in patients with metastatic breast cancer treated with
aromatase inhibitors. Oncology. 79:55–61. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Murphy LC, Skliris GP, Rowan BG, et al:
The relevance of phosphorylated forms of estrogen receptor in human
breast cancer in vivo. J Steroid Biochem Mol Biol. 114:90–95. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Sarwar N, Kim JS, Jiang J, et al:
Phosphorylation of ERalpha at serine 118 in primary breast cancer
and in tamoxifen-resistant tumours is indicative of a complex role
for ERalpha phosphorylation in breast cancer progression. Endocr
Relat Cancer. 13:851–861. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Murphy LC, Niu Y, Snell L and Watson P:
Phosphoserine-118 estrogen receptor-alpha expression is associated
with better disease outcome in women treated with tamoxifen. Clin
Cancer Res. 10:5902–5906. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Murphy LC, Weitsman GE, Skliris GP, et al:
Potential role of estrogen receptor alpha (ERalpha) phosphorylated
at Serine118 in human breast cancer in vivo. J Steroid Biochem Mol
Biol. 102:139–146. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Bhardwaj N, Carson MB, Abyzov A, Yan KK,
Lu H and Gerstein MB: Analysis of combinatorial regulation: scaling
of partnerships between regulators with the number of governed
targets. PLoS Comput Biol. 6:e10007552010. View Article : Google Scholar : PubMed/NCBI
|
